Characterization of Biotechnology Products: A Regulatory Perspective
|
|
- Belinda Waters
- 6 years ago
- Views:
Transcription
1 Characterization of Biotechnology Products: A Regulatory Perspective Laurie Graham Acting Team Leader FDA/CDER/OPS/OBP Division of Monoclonal Antibodies WCBP
2 Disclaimer The views and opinions expressed should not be used in place of regulations, published FDA guidance, or discussions with the Agency 2
3 Characterization: Product and Process Understanding CQAs In vitro, animal, and clinical data, prior knowledge, and published information used to assess impact on PK/PD, potency, immunogenicity, and safety Enhanced approaches Increased product and process understanding Control Strategy Process Development and Characterization Process characterization studies to determine how CQAs are influenced by the manufacturing process and material attributes 3
4 Presentation Outline 1. CQA identification 2. Control Strategy 3. Assay Lifecycle Management Changing Analytics 4
5 Critical Quality Attributes Enhanced approaches Enhanced understanding of product and process CQAs In vitro, animal, and clinical data, prior knowledge, and published information used to assess impact on PK/PD, potency, immunogenicity, and safety Process Development and Characterization Studies to determine how CQAs are influenced by the manufacturing process and material attributes Control Strategy 5
6 Critical Quality Attributes A physical, chemical, biological, or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality (ICH Q8) 1. Define product heterogeneity 2. Preliminary CQA assessments and further studies 3. Identifying CQAs 6
7 Defining Heterogeneity ICH Q6B Characterization efforts should include assessments of - physiochemical properties - biological activity - immunochemical properties - purity - impurities 7
8 Heterogeneity of Biotechnology Products: ICH Q6B Product related variants Process related impurities - Host Cell Proteins, DNA, raw materials, leachables/extractables Process Contaminants - Adventitious agents 8
9 Examples of Mab Product Related Variants In addition - Aggregation/particulates - Fragmentation - Glycation, etc Arthur J Chirino & Anthony Mire-Sluis Nature Biotechnology 22, (2004) 9
10 Regulatory Expectations: CQAs The structural and functional complexity of biotechnology proteins makes identification of a product s critical quality attributes challenging as a large number of attributes need to be assessed Expect some information at phase 1 with continued refinement during development For enhanced approaches, CQA identification generally more systematic, detailed, and involves the use of formal risk assessment tools and CQA score 10
11 CQA assessments and Further Studies: Product Variants Non-clinical and clinical data, prior knowledge, published information are used to assess impact on PK/PD, activity, immunogenicity, safety, etc. Additional Studies: - in vitro: variants assessed for bioactivity, antigen and Fc binding including FcRn binding (PK). Involves isolation/enrichment/generation of variants - in vivo: variants assessed during animal or clinical studies 11
12 Examples of CQA Risk Assessment Tools Sponsor 1 and 2: Severity x Uncertainty - Activity, safety, immunogenicity, PK/PD Sponsor 3: Impact x Probability x Uncertainty - Includes process capability and detectability - Consider safety and efficacy and strength of data Sponsor 4: Severity x Uncertainty - Activity, safety (including immunogenicity), PK Sponsor 5: Impact x Uncertainty - Effect on safety and efficacy Sponsor 6: Impact x Probability attribute impacted by process - Rationale for scoring not provided 12
13 CQA Identification Risk Assessment Tool Deficiencies Not all CQAs identified (impacts process characterization, design space, control strategy) Incorrect assessment of quality attributes in the risk assessment (e.g., exclusion of potential mechanism of action from evaluation) Underestimation of criticality of attribute because process capability and/or detectability were included in the CQA risk assessment 13
14 CQA Risk Assessment Tool Deficiencies Underestimation of the impact of an attribute because the risk assessment relied heavily on the lack of a clinical impact, but the product lots used clinically contained very low levels of the attribute Lack of assessment of attributes interactions Communicating information used in the CQA risk assessment Platform helpful throughout CQA identification process 14
15 Examples of General Characterization/CQA Issues Communicated by DMA for Original INDs Incomplete assessment of adventitious agent CQAs Raw material CQAs Not considering all potential product activities Clonality issues Additional attributes need to be considered (e.g. sub-visible particles < 10 µm) Specific product characteristic comments (e.g. IgG2, IgG4, IgM) Product specific immunogenicity comments CQAs based on formulation or presentation 15
16 Process Characterization Enhanced approaches Enhanced understanding of product and process CQAs In vitro, animal, and clinical data, prior knowledge, and published information used to assess impact on PK/PD, potency, immunogenicity, and safety Process Characterization Characterization studies to determine how CQAs are influenced by the manufacturing process and material attributes Control Strategy 16
17 Process Characterization In more traditional approaches, per ICH Q11, material specifications and process parameter ranges can be based primarily on batch process history and univariate experiments. Generally have some information on CQA impact by the manufacturing process and material attributes Enhanced approaches: Use preliminary risk assessment to identify material attributes and process parameters that will be studied further for their impact on CQAs. Systematically assess impact on CQAs in small scale univariate and multivariate studies. Establish process metric for CQA Platform helpful 17
18 Control Strategy Enhanced approaches Enhanced understanding of product and process CQAs In vitro, animal, and clinical data, prior knowledge, and published information used to assess impact on PK/PD, potency, immunogenicity, and safety Control Strategy Manufacturing Process Development Characterization studies to determine how CQAs are influenced by the manufacturing process and material attributes 18
19 Control Strategy Per ICHQ11, in a traditional approach, set-points and operating ranges are set narrowly to ensure process consistency. More emphasis is placed on the assessments of CQAs as end-product testing 19
20 Control Strategy: Benefits from Enhanced Approaches Testing strategy defined by CQA and process scoring along with strength of analytics Control strategy evolves throughout lifecycle with CQAs, process understanding, and changing analytics Flexibility in operating ranges and broader CQA acceptance criteria Testing strategy is more meaningful and efficient - Relevant assays with CQA testing to include IPC, lot release, stability, comparability, monitoring, etc Elements of an enhanced approach provide for control strategy benefits without a design space 20
21 CQA Acceptance Criteria Increased quality attribute knowledge can be used to broaden the acceptable range for some attributes so that they extend well outside manufacturing, clinical, (and potentially process characterization experience) While the range requested for the attribute itself may be acceptable, process/product knowledge would be needed to support the conditions that would result in an unexpected attribute result 21
22 General Considerations for Replacing an Existing Analytical Method Performance parameters of the new assay should be the same or better than the existing assay The stability indicating properties of the new assay should be the same or better than the existing assay If new product related variants or process related impurities are seen with the new assay, information from retain samples should be provided demonstrating that the variants/impurities are not new If making a major change in how a quality attribute is measured: - Assess consistency and comparability across multiple lots 22
23 Analytical Updates with Enhanced Approaches Analytical updates to assays that detect and monitor specific attributes (i.e. specific post-translational modification vs. charge assay) Assessment of analytical changes depends upon confidence that old assay does not provide meaningful CQA data not captured by new assay - Confidence that assessments to date have identified CQAs - Strength of the process/material and product understanding - Confidence in the proposed control strategy 23
24 Summary A thorough characterization- start early QbD experiences in DMA have revealed some common issues, but the inclusion of enhanced elements into DS development and manufacturing has significantly increased product and process understanding and resulted in control strategy benefits, even in the absence of a design space While the use of new analytics can provide benefits over existing assays or measure an emerging quality attribute, their implementation is often challenging. Appropriately store retain samples! 24
25 Acknowledgements Patrick Swann, Deputy Director, DMA Barbara Rellahan, Team Leader, DMA Jeffrey Baker, Deputy Director, OBP Regulatory Science Policy Branch, DMA 25
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences
Risk Assessments for Host Cell Protein Control Strategies: CDER Experiences Laurie Graham FDA/CDER Office of Pharmaceutical Quality (OPQ) Office of Policy for Pharmaceutical Quality (OPPQ) 1 Disclaimer
More informationCritical Quality Attributes for Biotechnology Products: A Regulatory Perspective
Critical Quality Attributes for Biotechnology Products: A Regulatory Perspective Patrick G. Swann, Ph.D. Deputy Director Division of Monoclonal Antibodies Office of Biotechnology Products Office of Pharmaceutical
More informationPrioritizing and Managing Key CMC Elements
Prioritizing and Managing Key CMC Elements Using 21 st Century Principles during Early Development Laurie Graham Product Quality/CMC Reviewer FDA/CDER/OPS/OBP Division of Monoclonal Antibodies 1 Disclaimer
More informationA Regulator s Perspective on Risk Based and Phase Appropriate Comparability. Marjorie Shapiro, Ph.D. Division of Monoclonal Antibodies OBP, CDER,FDA
A Regulator s Perspective on Risk Based and Phase Appropriate Comparability Marjorie Shapiro, Ph.D. Division of Monoclonal Antibodies OBP, CDER,FDA WCBP 2014 Outline Reasons for Changes Comparability ICH
More informationRegulatory perspective on setting clinically relevant specifications. Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products
Regulatory perspective on setting clinically relevant specifications Joslyn Brunelle, PhD Team Leader Office of Biotechnology Products Disclaimer The views and opinions expressed should not be used in
More informationMass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations
Mass Spectrometry for Characterization of Monoclonal Antibodies: Regulatory Considerations Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER Food and Drug Administration
More informationIdentification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy
Identification of Critical Product Quality Attributes: Impact of Product Variants on Safety and Efficacy Ziping Wei, Ph.D. Analytical Biochemistry MedImmune January 25, 2010 Outline Why do we need to identify
More informationCASE STUDY: THE USE OF PRIOR KNOWLEDGE IN ESTABLISHMENT OF AN INTEGRATED CONTROL STRATEGY AND CLINICALLY RELEVANT SPECIFICATIONS
CASE STUDY: THE USE OF PRIOR KNOWLEDGE IN ESTABLISHMENT OF AN INTEGRATED CONTROL STRATEGY AND CLINICALLY RELEVANT SPECIFICATIONS BARBARA RELLAHAN MS, PHD DIRECTOR, PRODUCT QUALITY PRESENTATION OUTLINE
More informationRegulatory Perspective on Analytical Method Validation During Product Development
Regulatory Perspective on Analytical Method Validation During Product Development CASSS CMC Strategy Forum 2018 Jacek Cieslak CDER/OPQ/OBP FDA Disclaimer This presentation reflects the views of the author
More informationThe Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives
The Role of Mass Spectrometry for Developing Biotherapeutics: Regulatory Perspectives Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products CDER/FDA CASSS, Applications of
More informationChallenges with Establishing a Control Strategy for Biosimilars
Challenges with Establishing a Control Strategy for Biosimilars FDA/PQRI Conference on Advancing Product Quality Bethesda, MD October 5 th Barbara Rellahan MS, PhD Director, Product Quality Amgen Inc Integrated
More informationComparability to establish Biosimilarity
Comparability to establish Biosimilarity CMC Strategy Forum Europe 2014, Sorrento, Italy Jan Visser, Head Global Analytical Characterization & Bioanalytics Sandoz Biopharmaceuticals, Hexal AG, Germany
More informationA Late-Stage Monoclonal Antibody in the FDA QbD Pilot Program: Moving from Concepts to Implementation
A Late-Stage Monoclonal Antibody in the FDA QbD Pilot Program: Moving from Concepts to Implementation Ron Taticek, Ph.D., Director Pharma Technical Regulatory Genentech, Inc. South San Francisco, CA WCBP
More informationRegulatory Considerations on. Office of Biotechnology Products
Regulatory Considerations on Multiproduct t Facilities for Biotechnology Products Jun Park, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA 2011 CASSS CMC Strategy
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationFDA Public Hearing: Approval Pathway for Biosimilar. Products. November 2-3, 2010
FDA Public Hearing: Approval Pathway for Biosimilar and Interchangeable Biological Products November 2-3, 2010 1 The Biotechnology Industry Organization Over 1,100 members, including biotechnology companies,
More informationExpectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective
Expectations for Analytical Characterisation in the Evaluation of Biosimilarity: A Regulator`s Perspective Christian Mayer AGES - Austrian Agency for Health and Food Safety Analytical Technologies Europe
More informationConsiderations in Setting Specifications
EBE Concept Paper Considerations in Setting Specifications March 28, 2013 European Biopharmaceutical Enterprises (EBE), a specialised group of EFPIA Leopold Plaza Building Rue du Trône 108 BE-1050 Brussels
More informationFDA recommendations for comparability studies to support manufacturing changes. Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA
FDA recommendations for comparability studies to support manufacturing changes Joslyn Brunelle, PhD Office of Biotechnology Products OPQ/CDER/FDA The views and opinions expressed here should not be used
More informationImplementing the Principles of Quality by
Corporate Research Implementing the Principles of Quality by Design for Early Stage Gene Therapy Products Michael Kelly Gene Therapy Development WCBP, Jan 23-25 th, 2012 Overview Gene Therapy V s Protein
More informationLessons Learned from QbD Application of Biologics in Japan: Perjeta Case
Lessons Learned from QbD Application of Biologics in Japan: Perjeta Case Mikio Suzuki CMC Development Dept., Regulatory Affairs Chugai Pharmaceutical Co.,Ltd. Outline Introduction of Perjeta Timeline up
More informationApplication of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols
Joint BWP/QWP/GMDP IWG Industry European Workshop on Lifecycle Management Application of ICH Q12 Tools and Enablers Post-Approval Lifecycle Management Protocols 1 Outline Introduction: evolution of PACMP
More informationAPPLYING SCIENTIFIC CONSIDERATIONS AND STATISTICAL APPROACHES IN ANALYTICAL SIMILARITY ASSESSMENT
APPLYING SCIENTIFIC CONSIDERATIONS AND STATISTICAL APPROACHES IN ANALYTICAL SIMILARITY ASSESSMENT JENNIFER LIU CASSS CMC STRATEGY FORUM EUROPE 2017, MAY 22-24 BIOSIMILAR DEVELOPMENT BEGINS WITH THOROUGH
More informationCell Therapy Product Manufacturing Considerations. July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D.
Cell Therapy Product Manufacturing Considerations July 17, 2017 CMC Strategy Forum Mo Heidaran, Ph.D. Office of Tissues and Advanced Therapies FDA/CBER Overview Establishing Manufacturing Control Applying
More informationCQAs for C> Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline
CQAs for C> Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development
More informationICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological entities)
May 2011 EMA/CHMP/ICH/425213/2011 ICH/ Committee for medicinal products for human use (CHMP) ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/biological
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationAntibody-Drug Conjugate Characterization and Quality Assurance
Antibody-Drug Conjugate Characterization and Quality Assurance Sarah Kennett Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA October 12, 2011 1 Disclaimer The views and
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More informationGuideline for the Quality, Safety, and Efficacy Assurance of Follow-on Biologics
Provisional Translation (as of April 19, 2013) PFSB/ELD Notification No. 0304007 March 4, 2009 To: Prefectural Health Department (Bureau) From: Evaluation and Licensing Division, Pharmaceutical and Food
More informationA Regulatory Perspective on Characterization and Control of Process-Related Impurities
A Regulatory Perspective on Characterization and Control of Process-Related Impurities Christopher Downey, PhD FDA/CDER Office of Biotechnology Products CASSS Bay Area Discussion Group June 2017 Disclaimer
More informationA FDA Product Reviewer s Perspective on Building A Quality Dossier
A FDA Product Reviewer s Perspective on Building A Quality Dossier CASSS Mid-West Discussion Group October 29, 2015 University Center of Lake County, Grayslake, IL Howard Anderson, PhD Team Lead Product
More informationDeveloping BIOSIMILARS The process and quality standards
Developing BIOSIMILARS The process and quality standards Amgen is a leader in biologics, with over 35 years of experience in the discovery, research, development, and manufacturing of science-based medicines.
More informationComparability of Biotechnology Derived Protein Products: Lessons from the U.S Experience
Comparability of Biotechnology Derived Protein Products: Lessons from the U.S Experience WCBP 2010, 14th Symposium on the Interface of Regulatory and Analytical Sciences for Biotechnology Health Products
More informationClinical qualification of specifications - a Regulator s view
Clinical qualification of specifications - a Regulator s view Mats Welin Medical Products Agency, Uppsala, Sweden Disclaimer: The opinions expressed are my own and do not necessarily represent those of
More informationParadigm Shift in Comparability Assessment:
Paradigm Shift in Comparability Assessment: How Quality by Design (QbD) and Process Analytical Technology (PAT) can improve Structure-Activity Relationship (SAR) evaluation and its relevance to comparability
More informationPreclinical Development Drugs. Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015
Preclinical Development Drugs Darrin Cowley PhD Executive Director Amgen BioBoot Camp 2015 Product Development: Development process: File Approval Drug Discovery Preclinical Phase 1 Phase 2 Phase 3 Lifecycle
More informationChanges to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodi
Changes to a Potency Bioassay for Biotechnology Products: a Regulatory Perspective Kathleen A. Clouse, Ph.D., Director Division of Monoclonal Antibodies Office of Biotechnology Products Center for Drug
More informationRegulatory Challenges for the Licensure of Future Vaccines
Regulatory Challenges for the Licensure of Future Vaccines Tong Wu, Ph.D. Bacterial & Combination Vaccine Division, BGTD, Health Canada June 26-29, 2018, Seoul, Korea, the Global Bio Conference 1 Disclaimer
More informationAMGEN S ATTRIBUTE BASED CONTROL STRATEGIES TOM MONICA DIRECTOR, CMC LIFECYCLE MANAGEMENT, AMGEN INC.
AMGEN S ATTRIBUTE BASED CONTROL STRATEGIES TOM MONICA DIRECTOR, CMC LIFECYCLE MANAGEMENT, AMGEN INC. 1 Attribute based control strategies Attribute based control strategies are a fundamental element of
More informationNotice Our file number:
June 15, 2015 Notice Our file number: 15-107053-353 Adoption of ICH 1 Guidance: Q5E: Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process Health Canada
More informationThe Role of Bioassays in the Determination of Critical Quality Attributes
The Role of Bioassays in the Determination of Critical Quality Attributes Aparna Deora, Ph.D. Associate Research Fellow Pfizer BioTherapeutics January 25, 2010 Outline of Talk What is a Critical Quality
More informationRegulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank
Regulatory Consideration for Biotechnology Products: Clonality of the Production Cell Bank Rashmi Rawat, Ph.D. Office of Biotechnology Products OPQ/CDER/FDA Informa Life Sciences Annual Cell Line Development
More informationJustification of Specifications (JOS): What Product and Process Development was all About. Christopher A Bravery
Justification of Specifications (JOS): What Product and Process Development was all About Christopher A Bravery cbravery@advbiols.com 1 The Importance of Characterisation 2 http://www.advbiols.com/documents/importance
More informationAnalytical Tools for Higher Order Structure Assessment in Comparability and Biosimilarity
Analytical Tools for Higher Order Structure Assessment in Comparability and Biosimilarity Brad Jordan, PhD Director, Global Regulatory and R&D Policy Amgen Inc. CASSS HOS 2018 Providence, RI How good are
More informationBiosimilars China Guideline. Dr Dr Michel Mikhail
Biosimilars China Guideline Dr Dr Michel Mikhail 1 Contents Regulatory context of biologicals in China Decree 28 issued by SFDA October 2007 Proposed biosimilars guideline 10/29/14 Reference drugs to use
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationMay 16-18, 2011 Beijing, China. Mark Rosolowsky, Ph.D. Vice President, Bristol-Myers Squibb
What You Should Know When You Make Manufacturing Changes to Biotechnology Products May 16-18, 2011 Beijing, China Mark Rosolowsky, Ph.D. Vice President, Global Regulatory Sciences-CMC Bristol-Myers Squibb
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationPractical challenges in the CMC development of biosimilars. Simon Hotchin Executive Director Regulatory Affairs Amgen Inc.
Practical challenges in the CMC development of biosimilars Simon Hotchin Executive Director Regulatory Affairs Amgen Inc. Overview Introduction Statistical methodologies in the assessment of analytical
More informationMANUFACTURING CONTROL STRATEGY FOR CELL, GENE AND TISSUE PRODUCTS Christopher A Bravery
MANUFACTURING CONTROL STRATEGY FOR CELL, GENE AND TISSUE PRODUCTS Christopher A Bravery CBRAVERY@ADVBIOLS.COM 1 INTRODUCTION What is a manufacturing control strategy? Why is it important? Common issues
More informationANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES
ANTIBODY DRUG CONJUGATES AND BISPECIFIC ANTIBODIES: SCIENTIFIC & REGULATORY CHALLENGES AND OPPORTUNITIES Brian DiPaolo 08 June 2017 CASSS Midwest Discussion Group Agenda Introduction Antibody Drug Conjugates
More informationExamples of regulatory expectations for analytical characterization and testing
Examples of regulatory expectations for analytical characterization and testing AT Europe 2016, 18 March 2016 Vicki Venizelos Quality RA B.V. Leiden, the Netherlands Overview What are the regulatory expectations?
More informationThe United States Pharmacopeia Strategy on Biotherapeutic Products Standards. Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts
The United States Pharmacopeia Strategy on Biotherapeutic Products Standards Jaap Venema, Ph.D. Chief Science Officer & Chair, Council of Experts U.S. Pharmacopeia Who We Are Scientific, independent, volunteer-driven,
More informationQbD (Quality by Design) Has industry benefited from this? WHITE PAPER.
WHITE PAPER www.makrocare.com/consulting There are many facets to engineering for a healthier world. It is important to understand what surrounds us today and look into what we believe will surround us
More informationCMC Strategy Forum Europe May Killarney, Ireland.
www.pei.de CMC Strategy Forum Europe 2015 22-24 May Killarney, Ireland. Technical innovations impact on regulatory expectations for product characterization Steffen Gross Head, Section Monoclonal and Polyclonal
More informationANALYTICAL VALIDATION CHALLENGES DURING THE RAPID DEVELOPMENT OF KEYTRUDA
ANALYTICAL VALIDATION CHALLENGES DURING THE RAPID DEVELOPMENT OF KEYTRUDA January 29, 2018 CMC Strategy Forum Industry Considerations for Phase-Appropriate Method Validations Athena Nagi Abstract and Outline
More informationCASSS CMC Strategy Forum Barcelona, Spain. EBE Satellite Session Comparability Concept Paper 21 st March 2011
CASSS CMC Strategy Forum Barcelona, Spain EBE Satellite Session Comparability Concept Paper 21 st March 2011 Aim of concept paper Points to consider in planning and undertaking of comparability exercise
More informationControl strategy and validation. Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA
Control strategy and validation Emanuela Lacana PhD Office of Biotechnology Products CDER/FDA 1 Disclaimer The views and opinions expressed in this presentation are those of the speaker and should not
More informationPerformance Based Regulatory Assessment
Performance Based Regulatory Assessment Leveraging the Depth of Industry Knowledge with the Breadth of Regulator Knowledge FDA/PQRI Conference 6 October 2015 Bethesda, MD roger nosal Vice President & Head
More informationRe: Docket No. FDA-2017-D-5525: Statistical Approaches to Evaluate Analytical Similarity
November 21 st, 2017 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA-2017-D-5525: Statistical Approaches to Evaluate
More informationEvolution of Quality Assessments Recent Trends in FDA Queries. Mike Saleh, Pfizer Inc.
Evolution of Quality Assessments Recent Trends in FDA Queries Mike Saleh, Pfizer Inc. Outline 1. Background 2. Assessment of Information Requests from Recent NDAs 3. Distribution of queries (by focus area)
More informationCOPYRIGHTED MATERIAL QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS. Rohin Mhatre and Anurag S. Rathore 1.1 INTRODUCTION
1 1.1 INTRODUCTION QUALITY BY DESIGN: AN OVERVIEW OF THE BASIC CONCEPTS Rohin Mhatre and Anurag S. Rathore The premise of Quality by Design (QbD) is that the quality of the pharmaceutical product should
More informationPLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS
PLANNING FOR SUCCESS: A CMC STRATEGY FOR BIOSIMILARS Louise Angell Lead Scientist 10th Biosimilars & Follow-On Biologics Congregation 9 th May 2017 Copyright @ 2017 Covance. All rights Reserved Overview
More informationAn FDA Perspective on the Implementation of State-of-the-Art Analytical Methods for the Development of Therapeutic Proteins
An FDA Perspective on the Implementation of State-of-the-Art Analytical Methods for the Development of Therapeutic Proteins Marjorie Shapiro, Ph.D. Office of Biotechnology Products/FDA WCBP 2018 Technical
More informationOBP s MARJORIE SHAPIRO ON ANALYTICAL SIMILARITY IN BIOSIMILAR APPROVAL
OBP s MARJORIE SHAPIRO ON ANALYTICAL SIMILARITY IN BIOSIMILAR APPROVAL In a session on biosimilar regulatory issues at the 2016 PDA/FDA Joint Regulatory Conference in September, Office of Biotechology
More informationPilot study linking CMC Analytical data with Clinical data
Pilot study linking CMC Analytical data with Clinical data John O Hara, UCB-Celltech, UK 5 May 2015 Support for pilot study 2 individuals New team Project support Pilot Study Company policy CQA What did
More informationScientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation
More informationDemonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle
Process Performance Qualification Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle Wendy Zwolenski Lambert, CQM/OE, RAC CMC Strategy Forum January 28, 2013 aligns
More informationDefining Product Quality Using Analytical Methods. Reed Harris Senior Staff Scientist, Pharma Technical Development
Defining Product Quality Using Analytical Methods Reed Harris Senior Staff Scientist, Pharma Technical Development CE Pharm 2015, Brooklyn NY, 21-Sep-2015 How to Define Suitable Product Quality? 2 What
More informationSpecifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products
ICH-GCG ASEAN Training Workshop 30th 31stMay 2011, Kuala Lumpur, Malaysia Federal Institute for Drugs Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products Dr.
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationSimilar biological medicinal product
SSPT, Tunis 13 November 2009 K. HO, Biological department - Biological medicinal product K. HO, Biological department Biological medicinal product Spectrum of complexity Spectrum of complexity Aspirin
More informationQuality attributes impacting immunogenicity of therapeutic proteins
www.pei.de Quality attributes impacting immunogenicity of therapeutic proteins Workshop on immunogenicity assessment of biotechnology-derived therapeutic proteins 9th March 2016 (EMA, Room 3A) Steffen
More informationEuropean Bioanalysis Forum
European Bioanalysis Forum Alternative Approaches for Assessment of Drug Neutralizing Activity of ADA Responses Presenter: Arjen Companjen (on behalf of EBF topic team 19) EIP meeting Lisbon 25 February
More informationBeing Clinically Relevant While Setting Specifications
Being Clinically Relevant While Setting Specifications CASSS Midwest Forum Hyatt Regency St. Louis, MO March 15, 2018 Aparna Deora, Ph.D. Biotherapeutics Pharmaceutical Sciences Analytical Research & Development
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationDr. Earl Dye CMC/GMP Considerations for Expedited Development Programs
Dr. Earl Dye CMC/GMP Considerations for Expedited Development Programs Earl Dye is Director of Technical Regulatory Policy in Genentech s Washington, DC Regulatory Affairs Office, and is the FDA Liaison
More informationAnalytical similarity: Lessons from the first US biosimilar
Analytical similarity: Lessons from the first US biosimilar 2nd FDA/PQRI Conference on Advancing Product Quality Oct. 5-7, 2015 Corinna Sonderegger, Head Pharmaceutical Development Sandoz Biopharmaceuticals,
More informationPMDA Perspective on Specifications for Biotechnological Products
WCBP 2016, January 26 28, 2016, The Mayflower Hotel, Washington, DC, USA PMDA Perspective on Specifications for Biotechnological Products Yasuhiro Kishioka, Ph.D. Principal Reviewer Office of Cellular
More informationQuality-by-Design for Biotechnology Products: Facilitating Implementation
Quality-by-Design for Biotechnology Products: Facilitating Implementation IMPLEMENTATION of QbD and PAT: A REGULATORY PERSPECTIVE An IFPAC-2010 Pre-Conference Workshop Baltimore, MD 2/1/2010 Steven Kozlowski,
More informationDevelop A Highly Similar" Biosimilar Compound: Lessons Learnt
Develop A Highly Similar" Biosimilar Compound: Lessons Learnt Hui-Chun Li, Ph.D. Sr. Manager of Process Science 2015 Feb 05 3rd Biologics World Taiwan 2015 SPIN OFF ACQUISITION Development Center for Biotechnology
More informationRegulatory Updates for Biopharmaceutical Products:FDA Perspective
Regulatory Updates for Biopharmaceutical Products:FDA Perspective CMC Strategy Forum Europe 2016 Sarah Kennett Division of Biotechnology Review and Research I Office of Biotechnology Products OPQ,CDER,
More informationSession 2-Product Design FIM to commercial for a lyophilised (NBE) product Michael Siedler, Abbvie
Joint BWP / QWP workshop with stakeholders in relation to prior knowledge and its use in regulatory applications Session 2-Product Design FIM to commercial for a lyophilised (NBE) product Michael Siedler,
More informationScientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products
Scientific and Regulatory Perspectives on Measuring Protein Aggregation of Biotechnology Products Ashutosh Rao, Ph.D. Chief, Laboratory of Applied Biochemistry Division of Biotechnology Review and Research
More informationQuality by Design Considerations for Analytical Procedures and Process Control
Quality by Design Considerations for Analytical Procedures and Process Control Moheb M. Nasr, Ph.D. ONDQA/CDER/FDA IFPAC 2009 Baltimore, MD January 26, 2009 1 Outline Background on FDA Initiatives and
More informationEGA s Perspective on the Draft Quality Guideline
EGA s Perspective on the Draft Quality Guideline London, 31 October 2013 JOERG WINDISCH, Ph.D. Chief Science Officer, Sandoz Biopharmaceuticals Chair European Biosimilars Group (EBG), EGA Sector Group
More informationManufacturing development and comparability assessments of Cell and Gene Therapy products for marketing in Europe
Manufacturing development and comparability assessments of Cell and Gene Therapy products for marketing in Europe Margarida Menezes Ferreira Senior Assessor at INFARMED PT expert at BWP/CHMP - EMA member
More informationFDA s Implementation of the Legal and Regulatory Framework for Biosimilars
FDA s Implementation of the Legal and Regulatory Framework for Biosimilars Sally Howard Deputy Commissioner for Policy, Planning, and Legislation 1 What are therapeutic biologics? Many biologics treat
More informationBiosimilars Scientific and Regulatory Considerations
Biosimilars Scientific and Regulatory Considerations Gustavo Grampp Regulatory Policy Director, Amgen Presented at Maryland Pharmacists Association meeting January 31, 2016 Program objectives 1. Review
More informationGuide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia
Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,
More informationVladimir Hanes, MD, USA
GaBI Educational Workshops 20 January 2015, Sheraton Maria Isabel Hotel & Towers, Mexico City, Mexico Vladimir Hanes, MD, USA Medical Director, Oncology Global Biosimilars Development, Amgen Inc GaBI Educational
More informationStatus of the ICH Q11 Guideline on Development and Manufacture of the Active Substance. Riccardo Luigetti Prague, 9 December 2009
European Medicines Agency Status of the ICH Q11 Guideline on Development and Manufacture of the Active Substance Riccardo Luigetti Prague, 9 December 2009 The views presented in these slides are those
More informationStrategies for IND Filing Success: Chemistry, Manufacturing and Controls
Strategies for IND Filing Success: Chemistry, Manufacturing and Controls October 21, 2016 Presented by: Sharon Ayd, Ph.D., MBA Chief Scientific Officer and SVP, Pharmaceuticals document contains proprietary
More informationRegulation of Active Pharmaceutical Ingredients (API)
Regulation of Active Pharmaceutical Ingredients (API) Stephan Rönninger Head External Affairs Europe, International Quality June 21, 2013 SINDUSFARMA / ANVISA / FIP-IPS Conference, Brasilia Agenda Regulations
More informationHow to Avoid Common Deficiencies in INDs and NDAs. Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER
How to Avoid Common Deficiencies in INDs and NDAs Ramesh Raghavachari, Ph.D. Branch Chief, Branch IX ONDQA/OPS/CDER 1 Structure of FDA Office of Commissioner Chief Scientist FOODS Medical Products & Tobacco
More informationArchived Content. This content was archived on June 24, 2013.
This content was archived on June 24, 2013. Archived Content Information identified as archived on the Web is for reference, research or recordkeeping purposes. It has not been altered or updated after
More informationQbD Concepts Applied to Qualification and Transfer of Analytical Methods
QbD Concepts Applied to Qualification and Transfer of Analytical Methods CMC Strategy Forum Latin America - 2014 Patrick Swann Senior Director Technical Development QbD = Quality by Design QbD - A systematic
More informationMaking the Transition to CE Methods and between CE Methods- An FDA Reviewer s Perspective
Making the Transition to CE Methods and between CE Methods- An FDA Reviewer s Perspective Sarah Kennett, Ph.D. Division of Monoclonal Antibodies Office of Biotechnology Products OPS/CDER/FDA October 15,
More information